The immunomodulatory properties of mesenchymal stem cells
The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Human mesenchymal stem cells modulate allogeneic immune cell responses
Aggarwal, S., & Pittenger, M. F. (2005) · Blood · doi:10.1182/blood-2004-04-1559 · Cited by 4,511
Di Nicola, M., Carlo-Stella, C., Magni, M., Milanesi, M., Longoni, P. D., Matteucci, P., Grisanti, S., & Gianni, A. M. (2002) · Blood · doi:10.1182/blood.v99.10.3838 · Cited by 3,226
Mesenchymal stem cells within tumour stroma promote breast cancer metastasis
Karnoub, A. E., Dash, A. B., Vo, A. P., Sullivan, A., Brooks, M. W., Bell, G. W., Richardson, A. L., Polyak, K., Tubo, R., & Weinberg, R. A. (2007) · Nature · doi:10.1038/nature06188 · Cited by 3,206 · cited 1×
“In adoptive transfer experiments, MSC cause weakly metastatic human breast carcinoma cells to acquire potent metastatic ability [82].”
BackgroundSacchetti, B., Funari, A., Michienzi, S., Di Cesare, S., Piersanti, S., Saggio, I., Tagliafico, E., Ferrari, S., Robey, P. G., Riminucci, M., et al. (2007) · Cell · doi:10.1016/j.cell.2007.08.025 · Cited by 2,226
Ren, G., Zhang, L., Zhao, X., Xu, G., Zhang, Y., Roberts, A. I., Zhao, R. C., & Shi, Y. (2008) · Cell Stem Cell · doi:10.1016/j.stem.2007.11.014 · Cited by 2,101 · cited 1×
“There are other inflammatory cytokines, such as TNF-α or IL-1β, that can license MSC immunosuppression [54] and determine substantial changes in their immunophenotypic profile.”
BackgroundHuman mesenchymal stem cells modulate B-cell functions
Corcione, A., Benvenuto, F., Ferretti, E., Giunti, D., Cappiello, V., Cazzanti, F., Risso, M., Gualandi, F., Mancardi, G. L., Pistoia, V., et al. (2006) · Blood · doi:10.1182/blood-2005-07-2657 · Cited by 1,767
Fibrotic disease and the TH1/TH2 paradigm
Wynn, T. A. (2004) · Nature Reviews Immunology · doi:10.1038/nri1412 · Cited by 1,765
Mesenchymal Stem Cell Homing: The Devil Is in the Details
Karp, J. M., & Leng Teo, G. S. (2009) · Cell Stem Cell · doi:10.1016/j.stem.2009.02.001 · Cited by 1,445 · cited 1×
“In fact, despite the evidence that MSC can certainly be effective, the benefits do not appear to correlate with the extent of engraftment, which is, in general, negligible [67].”
BackgroundMechanisms involved in the therapeutic properties of mesenchymal stem cells
da Silva Meirelles, L., Fontes, A. M., Covas, D. T., & Caplan, A. I. (2009) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2009.10.002 · Cited by 1,436
Macrophage Polarization Comes of Age
Mantovani, Sica, & Locati, M. (2005) · Immunity · doi:10.1016/j.immuni.2005.10.001 · Cited by 1,259 · cited 1×
“It seems more plausible, considering the comparison with monocytes, that there is a continuum of different activation states determined by the combination of different stimuli [63].”
BackgroundWaterman, R. S., Tomchuck, S. L., Henkle, S. L., & Betancourt, A. M. (2010) · PLoS ONE · doi:10.1371/journal.pone.0010088 · Cited by 1,238
Suppression of Antitumor Immunity by Stromal Cells Expressing Fibroblast Activation Protein–α
Kraman, M., Bambrough, P. J., Arnold, J. N., Roberts, E. W., Magiera, L., Jones, J. O., Gopinathan, A., Tuveson, D. A., & Fearon, D. T. (2010) · Science · doi:10.1126/science.1195300 · Cited by 1,134 · cited 1×
“Depleting FAP-expressing cells in a subcutaneous model of pancreatic ductal adenocarcinoma permitted immunological control of growth [96].”
BackgroundIn Search of the In Vivo Identity of Mesenchymal Stem Cells
da Silva Meirelles, L., Caplan, A. I., & Nardi, N. B. (2008) · Stem Cells · doi:10.1634/stemcells.2007-1122 · Cited by 1,077
Ortiz, L. A., DuTreil, M., Fattman, C., Pandey, A. C., Torres, G., Go, K., & Phinney, D. G. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0704421104 · Cited by 1,019
Interactions Between Human Mesenchymal Stem Cells and Natural Killer Cells
Sotiropoulou, P. A., Perez, S. A., Gritzapis, A. D., Baxevanis, C. N., & Papamichail, M. (2006) · Stem Cells · doi:10.1634/stemcells.2004-0359 · Cited by 956 · cited 1×
“Also, NK cytokine production is influenced by the interactionwithMSC, because IL-2-activated NK cells produce a reduced amount of IFN-γ, IL-10 and TNFα in the presence of MSC [39].”
BackgroundRuffell, D., Mourkioti, F., Gambardella, A., Kirstetter, P., Lopez, R. G., Rosenthal, N., & Nerlov, C. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0908641106 · Cited by 626 · cited 1×
“The functional deletion of the Cebpβ gene in infiltrating macrophages prevents their ability to acquire an M2 phenotype and, whilst maintaining their ability to remove necrotic tissue from injured muscle, lose their capacity to promote tissue repair [52, 53, 73].”
BackgroundInflammation and tumor microenvironments: defining the migratory itinerary of mesenchymal stem cells
Spaeth, E., Klopp, A., Dembinski, J., Andreeff, M., & Marini, F. (2008) · Gene Therapy · doi:10.1038/gt.2008.39 · Cited by 579 · cited 4×
“MSC to the tumour site, including IL-8, TGF-β1, neurotropin (NT)-3 [75], VEGF [76], EGF, hepatocyte growth factor [77] and PDGF [78].”
BackgroundInfluentialMesenchymal stem cells: a new strategy for immunosuppression and tissue repair
Shi, Y., Hu, G., Su, J., Li, W., Chen, Q., Shou, P., Xu, C., Chen, X., Huang, Y., Zhu, Z., et al. (2010) · Cell Research · doi:10.1038/cr.2010.44 · Cited by 575 · cited 1×
“Resolution of inflammation is crucial for tissue repair and involves a network of antiinflammatory activities produced by stromal cells [71].”
BackgroundMesenchymal stem cells derived from bone marrow favor tumor cell growth in vivo
Zhu, W., Xu, W., Jiang, R., Qian, H., Chen, M., Hu, J., Cao, W., Han, C., & Chen, Y. (2006) · Experimental and Molecular Pathology · doi:10.1016/j.yexmp.2005.07.004 · Cited by 386 · cited 1×
“By exerting an anti-proliferative and anti-apoptotic activity, MSC increase tumour stem cell life span whilst fuelling the growth of tumour cell progeny [42, 81].”
BackgroundMesenchymal progenitor cells as cellular vehicles for delivery of oncolytic adenoviruses
Komarova, S., Kawakami, Y., Stoff-Khalili, M. A., Curiel, D. T., & Pereboeva, L. (2006) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-05-0334 · Cited by 302 · cited 1×
“Injected MSC loaded with oncolytic adenovirus induced a higher survival of mice compared with the systemic injection of virus, in a model of ovarian cancer [99].”
BackgroundReview of Mesenchymal Stem Cells and Tumors: Executioner or Coconspirator?
Feng, B., & Chen, L. (2009) · Cancer Biotherapy and Radiopharmaceuticals · doi:10.1089/cbr.2009.0652 · Cited by 83
Mesenchymal stem cells: an emerging tool for cancer targeting and therapy
Fritz, V., & Jorgensen, C. (2008) · Current Stem Cell Research & Therapy · doi:10.2174/157488808783489462 · Cited by 79
Cited by
Zhao, J., Li, X., Hu, J., Chen, F., Qiao, S., Sun, X., Gao, L., Xie, J., & Xu, B. (2019) · Cardiovascular Research · doi:10.1093/cvr/cvz040 · Cited by 769
Mesenchymal stem cell: An efficient mass producer of exosomes for drug delivery
Yeo, R. W. Y., Lai, R. C., Zhang, B., Tan, S. S., Yin, Y., Teh, B. J., & Lim, S. K. (2013) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2012.07.001 · Cited by 746
Mesenchymal stem cell exosomes
Lai, R. C., Yeo, R. W. Y., & Lim, S. K. (2015) · Seminars in Cell & Developmental Biology · doi:10.1016/j.semcdb.2015.03.001 · Cited by 570
Exosomes for drug delivery—A novel application for the mesenchymal stem cell
Lai, R. C., Yeo, R. W. Y., Tan, K. H., & Lim, S. K. (2013) · Biotechnology Advances · doi:10.1016/j.biotechadv.2012.08.008 · Cited by 546
Mechanisms underlying the protective effects of mesenchymal stem cell-based therapy
Fan, X.-L., Zhang, Y., Li, X., & Fu, Q.-L. (2020) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-020-03454-6 · Cited by 535
Metadata
- Authors
- Marigo, I., & Dazzi, F.
- Venue
- Seminars in Immunopathology
- Published
- 2011-04-19
- Volume
- 33
- Issue
- 6
- Pages
- 593-602
- ISSN
- 1863-2297 (ISSN-L)
- 1863-2300
- OpenAlex
- W2016177057
- Cited by
- 162
- References
- 22
- FWCI
- 7.65
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.